Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
7.03
+0.10 (1.44%)
At close: Mar 18, 2026, 4:00 PM EDT
7.04
+0.01 (0.14%)
After-hours: Mar 18, 2026, 7:18 PM EDT
Precision BioSciences Employees
Precision BioSciences had 67 employees as of September 30, 2025. The number of employees decreased by 41 or -37.96% compared to the same quarter last year.
Employees
67
Change
-41
Growth
-37.96%
Revenue / Employee
$511,403
Profits / Employee
-$682,448
Market Cap
173.83M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 67 | -41 | -37.96% |
| Jun 30, 2025 | 102 | -8 | -7.27% |
| Mar 31, 2025 | 107 | -2 | -1.83% |
| Dec 31, 2024 | 108 | -1 | -0.92% |
| Sep 30, 2024 | 108 | -7 | -6.09% |
| Jun 30, 2024 | 110 | -82 | -42.71% |
| Mar 31, 2024 | 109 | -88 | -44.67% |
| Dec 31, 2023 | 109 | -89 | -44.95% |
| Sep 30, 2023 | 115 | -79 | -40.72% |
| Jun 30, 2023 | 192 | 0 | - |
| Mar 31, 2023 | 197 | 7 | 3.68% |
| Dec 31, 2022 | 198 | 0 | - |
| Sep 30, 2022 | 194 | -32 | -14.16% |
| Jun 30, 2022 | 192 | -44 | -18.64% |
| Mar 31, 2022 | 190 | -47 | -19.83% |
| Dec 31, 2021 | 198 | -33 | -14.29% |
| Sep 30, 2021 | 226 | 3 | 1.35% |
| Jun 30, 2021 | 236 | 16 | 7.27% |
| Mar 31, 2021 | 237 | 12 | 5.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Heron Therapeutics | 128 |
| Arcturus Therapeutics Holdings | 111 |
| Nkarta | 105 |
| Korro Bio | 58 |
| Milestone Pharmaceuticals | 33 |
| Eledon Pharmaceuticals | 31 |
| Corbus Pharmaceuticals Holdings | 28 |
| AN2 Therapeutics | 22 |
DTIL News
- 1 day ago - Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript - Seeking Alpha
- 6 days ago - Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update - Business Wire
- 7 days ago - Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program - Business Wire
- 8 days ago - Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 - Business Wire
- 9 days ago - Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 - Business Wire
- 9 days ago - Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event - Business Wire
- 16 days ago - Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Business Wire
- 4 weeks ago - Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire